|کد مقاله||کد نشریه||سال انتشار||مقاله انگلیسی||ترجمه فارسی||نسخه تمام متن|
|5124312||1378442||2017||4 صفحه PDF||ندارد||دانلود کنید|
SummaryObjectivesThe study aims to (1) identify the botulinum toxin (BTX) dosing trend in a cohort of patients who received at least 20 injections for the treatment of adductor spasmodic dysphonia (ADSD), (2) describe two distinct BTX dosing trends in treating ADSD (a âclassicâ dosing trend that initially decreases before stabilizing, and a âfluctuatingâ dosing trend), and (3) determine if patients with the âclassicâ dosing trend differed in age or in dosing intervals from those with the âfluctuatingâ dosing trend.Study designThis is a retrospective case series.MethodsOf 149 patients who received a total of 2484 BTX injections for the treatment of spasmodic dysphonia in 1993â2013, 49 patients received at least 20 injections. The BTX dose and the interval between doses were recorded. The mean dose of injections 1â20 was determined. The age at initial injection, initial dose, and interval in days between treatments were compared for the âfluctuatingâ and âclassicâ groups.ResultsThe cohort exhibits a significant decrease in dose during the first 10â15 injections. The âfluctuatingâ group had a significantly shorter interval between injections (mean intervalâ=â97.09 days, SDâ=â29.41; mean intervalâ=â136.90 days, SDâ=â43.76, Pâ=â0.002). The mean age at initial dose was not significantly different between the âclassicâ and âfluctuatingâ groups.ConclusionsThe average BTX dose of patients with ADSD who receive long-term injections significantly decreases during the initial 10â15 injections before stabilizing. Patients who exhibit the âfluctuatingâ dosing pattern have a significantly shorter interval between injections than those with the âclassicâ dosing pattern.
Journal: Journal of Voice - Volume 31, Issue 1, January 2017, Pages 107-110